NASDAQ · BIVI
Healthcare · Biotechnology
$1.91
Down-$0.06 (-3.05%)
Updated Sep 11, 2026, 4:12 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BIVI closed at $1.91 after 20 trading sessions, up 22.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $1.95 | $1.99 | $1.89 | $1.91 | 261.85K |
| Sep 9, 2026 | $2.04 | $2.12 | $1.90 | $1.97 | 351.37K |
| Sep 8, 2026 | $2.055 | $2.20 | $2.00 | $2.07 | 320.03K |
| Sep 4, 2026 | $2.04 | $2.08 | $1.96 | $2.00 | 296.76K |
| Sep 3, 2026 | $2.02 | $2.1201 | $2.005 | $2.03 | 250.79K |
| Sep 2, 2026 | $2.25 | $2.27 | $2.0001 | $2.03 | 519.4K |
| Sep 1, 2026 | $2.30 | $2.45 | $2.18 | $2.24 | 486.56K |
| Aug 31, 2026 | $2.374 | $2.49 | $2.28 | $2.28 | 1.55M |
| Aug 28, 2026 | $2.20 | $2.25 | $2.1059 | $2.16 | 485.69K |
| Aug 27, 2026 | $2.09 | $2.22 | $2.00 | $2.19 | 763.38K |
| Aug 26, 2026 | $2.005 | $2.25 | $1.9673 | $2.11 | 922.45K |
| Aug 25, 2026 | $2.00 | $2.11 | $1.93 | $2.09 | 1.03M |
| Aug 24, 2026 | $1.812 | $2.145 | $1.76 | $2.14 | 2.17M |
| Aug 21, 2026 | $2.155 | $2.48 | $1.80 | $1.95 | 19.76M |
| Aug 20, 2026 | $1.545 | $2.39 | $1.4901 | $1.86 | 49.11M |
| Aug 19, 2026 | $1.30 | $1.44 | $1.14 | $1.34 | 42.47M |
| Aug 18, 2026 | $1.13 | $1.14 | $0.945 | $0.9644 | 10.54M |
| Aug 17, 2026 | $1.32 | $1.56 | $1.17 | $1.17 | 2.76M |
| Aug 14, 2026 | $1.415 | $1.515 | $1.245 | $1.40 | 2.12M |
| Aug 13, 2026 | $1.65 | $1.70 | $1.48 | $1.56 | 4.88M |
The latest Smart Investors Daily articles mentioning BIVI.
BIVI research
Company profile and research snapshot.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 1, 2024 | ThinkEquity | Buy | — |
| Nov 30, 2023 | Oppenheimer | Outperform | — |
| Aug 22, 2023 | Cantor Fitzgerald | Overweight | — |
| Jul 18, 2023 | Cantor Fitzgerald | Overweight | — |
| May 17, 2023 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Yahoo · Aug 31, 2026
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based...
Yahoo · Aug 31, 2026
Last Patient Last On-Site Visit Completed with Topline Data Release Targeted September 2026CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed. The Phase
ChartMill · Aug 21, 2026
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Benzinga · Aug 19, 2026
Gainers ZeroStack (NASDAQ:ZSTK) stock increased by 440.2% to $9.94 during Wednesday's regular session. The company's market cap stands at $4.4 million. Tenon Medical (NASDAQ:TNON) shares moved upwards by
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BIVI.
